BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer

Table 1 Screening TOP 10 gene by different algorithms of cytohubba

DMNC	MNC
HLA-DRB5	HLA-DRB1
PTPN22	HLA-DRA
CD74	MUC6
CD86	MUC5B
HLA-A	HLA-DRB5
HLA-DRB1	PER1
HLA-DRA	CSNK1E
PER1	BIRC3
CSNK1E	NOD2
BIRC3	PTPN22

DMNC: Density of maximum neighborhood component; MNC: Maximum neighborhood component.

Table 2 Genes screened by molecular complex detection

Cluster	Score	Nodes	Edges	Node IDs
1	3.333	4	5	GRIA2, GRIA4, TSPAN7, PRKCG
2	3.333	4	5	NOD2, TNFAIP3, BIRC3, TLR4
3	3	3	3	WNT10B, LRP5, WNT3A
4	3	3	3	HIST1H1E, HIST1H4E, HIST1H3J
5	3	3	3	HBB, HBA2, HBA1
6	3	3	3	GUCY1B3, GUCY1A3, PRKG1
7	3	3	3	HLA-DRA, GNAO1, HLA-DRB1
8	3	3	3	TPO, DDC, IL4I1
9	3	3	3	PER3, CSNK1E, PER1
10	3	3	3	MMP13, COL9A1, COL9A2
11	3	3	3	SPON2, ADAMTS9, SEMA5A

Table 3 Relationship between BIRC3 and clinical pathology in human epidermal growth factor receptor 2 (+) group, n (%)

	BIRClow group (n = 7)	BIRChigh group (n = 21)	P value
Sex (male)	6 (85.7)	19 (90.5)	1.000
Age (year)	63.71 ± 8.45	63.95 ± 8.52	0.9492
BMI (kg/m2)	22.94 ± 2.81	24.56 ± 3.40	0.2702
Tumor size (cm)	3.64 ± 2.34	4.90 ± 1.78	0.1462
Differentiation			0.4291
Poor	3 (42.9)	14 (66.7)
Moderate	4 (50.0)	6 (28.6)
High	0 (0.0)	1 (4.8)
T stage			0.030
1	1 (14.3)	0 (0)
2	2 (28.6)	2 (9.5)
3	4 (57.1)	2 (9.5)
4	0 (0.0)	17 (81.0)
N stage			0.245
0	3 (42.9)	5 (23.8)
1	2 (28.6)	9 (42.9)
2	2 (28.6)	3 (14.3)
3	0 (0.0)	4 (19.0)
M stage			-
0	7 (100.0)	19 (90.5)
1	0 (0.0)	2 (9.5)
TNM stage			0.016
I	1 (4.8)	0 (0.0)
II	2 (9.5)	0 (0.0)
III	4 (19)	19 (90.5)
IV	0 (0.0)	2 (9.5)
Survival			0.5711
Live	6 (85.7)	11 (52.4)
Dead	1 (14.3)	10 (47.6)
OS (month)
mean ± SD	31.43 ± 7.138	17.0 ± 8.63	0.0012
Median (range)	29 (22-43)	14 (8-45)	-
Recurrence			0.5711
No	6 (85.7)	10 (47.6)
Recurrence	1 (14.3)	11 (52.4)
DFS (month)
mean ± SD	24.14 ± 4.34	14.76 ± 9.89	0.0022
Median (range)	25 (17-29)	13 (2-45)	-

¹P calculated by fisher test.

²P calculated by t text.

BMI: Body mass index; TNM: Tumor node metastasis; OS: Overall survival; DFS: Disease-free survival.

Table 4 Relationship between BIRC3 and clinical pathology in human epidermal growth factor receptor 2 (-) group, n (%)

	BIRClow group (n = 23)	BIRChigh group (n = 37)	P value
Sex (male)	19 (82.6)	24 (81.1)	0.2701
Age (year)	65.43 ± 10.77	64.97 ± 7.58	0.1102
BMI (kg/m2)	23.46 ± 3.43	24.84 ± 3.77	0.8922
HER2			0.047
HER2 (-)	16 (69.6)	16 (43.2)
HER2 (+)	7 (30.4)	21 (56.8)
Tumor size (cm)	3.43 ± 2.02	4.59 ± 1.84	0.5002
Differentiation			0.489
Poor	9 (39.1)	24 (64.9)
Moderate	14 (60.9)	10 (27.0)
High	0 (0.0)	3 (8.1)
T stage			0.001
1	5 (13.5)	1 (2.7)
2	7 (18.9)	6 (16.2)
3	10 (27.0)	11 (29.7)
4	1 (2.7)	19 (51.4)
N stage			0.208
0	11 (29.7)	8 (21.6)
1	10 (27.0)	20 (54.1)
2	2 (5.4)	5 (13.5)
3	0 (0.0)	4 (10.8)
M stage			0.691
0	23 (100.0)	35 (94.6)
1	0 (0.0)	2 (5.4)
TNM stage			0.007
I	4 (10.8)	1 (2.7)
II	5 (13.5)	1 (2.7)
III	12 (32.4)	24 (64.9)
IV	2 (5.4)	11 (29.7)
OS (month)
mean ± SD	32.2 ± 16.33	21.81 ± 15.17	0.0152
Median (range)	33 (3-53)	15 (5-53)	-
DFS (month)
mean ± SD	26.74 ± 14.80	18.57 ± 14.21	0.0402
Median (range)	26 (3-52)	15 (2-53)	-

¹P calculated by fisher test.

²P calculated by t text.

BMI: Body mass index; TNM: Tumor node metastasis; OS: Overall survival; DFS: Disease-free survival.